Search results
Showing 31 to 45 of 49 results for cryotherapy
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.
View recommendations for IPG446Show all sections
Sections for IPG446
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for IPG788Show all sections
Source guidance details Comes from guidance Laparoscopic cryotherapy for renal cancer Number IPG405 Date issued August
applicable) Source guidance details Comes from guidance Cryotherapy for chronic rhinitis Number IPG771 Date issued September
Irreversible electroporation for treating prostate cancer (IPG768)
Evidence-based recommendations on irreversible electroporation for treating prostate cancer. This involves using electrical pulses to destroy the cancer cells.
View recommendations for IPG768Show all sections
Evidence-based recommendations on microwave ablation for treating liver metastases in adults. This involves using heat energy to destroy cancer cells.
Radiofrequency cold ablation for respiratory papillomatosis (IPG434)
Evidence-based recommendations on radiofrequency cold ablation for respiratory papillomatosis. This involves using an electrical current to dissolve or shrink the papillomas (non-cancerous growths).
View recommendations for IPG434Show all sections
Sections for IPG434
Percutaneous radiofrequency ablation for primary or secondary lung cancers (IPG372)
Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.
View recommendations for IPG372Show all sections
Sections for IPG372
Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.
Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.
View recommendations for IPG752Show all sections
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)
Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.
Focal therapy using cryoablation for localised prostate cancer (IPG423)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for IPG423Show all sections
Sections for IPG423
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (IPG497)
Evidence-based recommendations on endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy squamous cells.
This guidance has been updated and replaced by NICE interventional procedure guidance 405.